These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33189407)

  • 1. Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
    Mínguez Sabater A; Martínez Delgado S; Ladrón Abia P; Bastida G
    Gastroenterol Hepatol; 2022 Jan; 45(1):62-63. PubMed ID: 33189407
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous acral eruption related to secukinumab.
    Blackcloud P; Dupuy E; Kang Y; Smart C; Hsiao J
    Dermatol Online J; 2019 Jun; 25(6):. PubMed ID: 31329391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
    Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
    World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab-induced psoriasis in a patient with Crohn's disease.
    Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
    Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
    [No Abstract]   [Full Text] [Related]  

  • 5. Palisaded neutrophilic and granulomatous dermatitis in a rheumatoid arthritis patient after treatment with adalimumab.
    Umezawa Y; Ito K; Nakagawa H
    Eur J Dermatol; 2013; 23(6):910-1. PubMed ID: 24201093
    [No Abstract]   [Full Text] [Related]  

  • 6. Education and imaging. Gastrointestinal: Cutaneous reaction associated with loss of response to adalimumab.
    Hillemand CG; Leong RW
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1073. PubMed ID: 23782119
    [No Abstract]   [Full Text] [Related]  

  • 7. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
    Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
    Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
    [No Abstract]   [Full Text] [Related]  

  • 8. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
    Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
    J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
    [No Abstract]   [Full Text] [Related]  

  • 9. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.
    Gold SL; Magro C; Scherl E
    Gastroenterology; 2018 Oct; 155(4):981-982. PubMed ID: 29614303
    [No Abstract]   [Full Text] [Related]  

  • 10. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.
    Sauder MB; Glassman SJ
    Int J Dermatol; 2013 May; 52(5):624-8. PubMed ID: 23489057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease.
    Bressler B; Siegel CA
    Gastroenterology; 2014 Apr; 146(4):884-7. PubMed ID: 24576727
    [No Abstract]   [Full Text] [Related]  

  • 12. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.
    Hare NC; Hunt DP; Venugopal K; Ho GT; Beez T; Lees CW; Gibson R; Weller B; Satsangi J
    QJM; 2014 Jan; 107(1):51-5. PubMed ID: 22240391
    [No Abstract]   [Full Text] [Related]  

  • 14. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
    Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
    Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a link between the use of adalimumab and Henoch-Schönlein purpura?
    Park SJ; Shin JI
    J Crohns Colitis; 2013 Aug; 7(7):600. PubMed ID: 23318146
    [No Abstract]   [Full Text] [Related]  

  • 17. Solitary facial cutaneous chronic inflammatory lesions induced by anti-tumour necrosis factor-α antagonist.
    Haro-Gabaldón V; Ruiz Molina I; Haro-González-Vico V; Solís García E
    Clin Exp Dermatol; 2019 Jan; 44(1):80-82. PubMed ID: 30255515
    [No Abstract]   [Full Text] [Related]  

  • 18. Vedolizumab-induced acne in inflammatory bowel disease.
    Gilhooley E; Doherty G; Lally A
    Int J Dermatol; 2018 Jun; 57(6):752-753. PubMed ID: 29654701
    [No Abstract]   [Full Text] [Related]  

  • 19. Palmoplantar pustulosis by adalimumab in a patient with Crohn disease.
    Ortiz Salvador JM; Cubells Sánchez L; Subiabre Ferrer D
    Med Clin (Barc); 2016 Dec; 147(12):565. PubMed ID: 27431884
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.